Contrafect Corporation

Contrafect Corporation, a biotechnology firm, focuses on the development of new treatments for antibiotic-resistant infections. The corporation's primary goal is to address the growing global health challenge posed by resistant bacterial strains. Contrafect specializes in the use of lysins, a novel class of enzymes that target and destroy specific bacteria, offering a promising alternative to traditional antibiotics. Their research is critical in the pharmaceutical and healthcare industries, particularly as the need for new antimicrobials grows. Contrafect's innovative approach places it at the forefront of efforts to combat the rising threat of superbugs that traditional antibiotics can no longer control effectively, underscoring its significant role in advancing medical science.